Silobreaker.com    Log In
   My Page    Help   
360° SearchNetworkHot SpotsTrends
 
Advanced Search Options >>
Saturday, November 21, 2009 6:42 AM

Published 10/20/2009 by News-Medical.Net


Elan and Biogen Idec to present TYSABRI study data at ACG meeting

Elan Corporation, plc (NYSE: ELN) and Biogen Idec (NASDQ: BIIB) today announced multiple presentations at the American College of Gastroenterology (ACG) Annual Scientific Meeting, taking place October 23-28 in San Diego.

The posters and presentations during ACG will highlight TYSABRI (natalizumab) data in treating Crohns Disease. During...

Share this 

What others report on the same story

Elan to Highlight Tysabri Data in Crohn's Disea...
BusinessWire - Elan Corporation, plc (NYSE: ELN) and Biogen Idec (NASDQ: BIIB) today announced multiple presentations at the American College of Gastroenterology ... - [10/19/2009 - Forbes.com]
Elan to Highlight Tysabri Data in Crohn's Disea... - [10/19/2009 - Individual.com]
Elan to Highlight Tysabri Data in Crohn’... - [10/19/2009 - Business Wire]
Elan to Highlight Tysabri Data in Crohns Diseas... - [10/19/2009 - FinanzNachrichten.de]
Elan to Highlight Tysabri Data in Crohn’... - [10/19/2009 - Business Wire via MSN Money]
1

Related Stories

First Reported 10/23/2009 - Updated 10/24/2009 - 15 Documents (in Health)
Elan shares fall by 20pc as drug-linked disease cases rise
Shares in Elan plunged 20pc to ?3.42 in Dublin yesterday after its multiple sclerosis treatment Tysabri was linked to over 20 cases of a potentially fatal brain disease and the European drug watchdog said it was reviewing its use. Elan finished at ?3.42 ... [Irish Independent - 10/24/2009]
First Reported 10/22/2009 - Updated 10/22/2009 - 1 Documents (in Biology)
Johnson & Johnson - Click to view image in its original context
Johnson & Johnson
Elan focuses on boosting MS drug sales after selling stake to J&J
Kelly Martin, chief executive of Elan, said the Irish drugs group would focus on increasing sales of its multiple sclerosis drug Tysabri, following the sale of a stake... ... [FT.com - Health - 10/22/2009]
First Reported 10/20/2009 - Updated 10/21/2009 - 8 Documents
Biogen sinks on new worry over Tysabri
Biogen Idec has reported third-quarter earnings that topped expectations, but concern over the future of its multiple sclerosis drug Tysabri sent its shares down more than 2 percent.Revenue from sales of Tysabri rose 21 percent to USD 207 million in the ... [Ireland Business World - 10/21/2009]
First Reported 10/19/2009 - Updated 10/19/2009 - 6 Documents (in Internet & IT)
Biogen Idec - Click to view image in its original context
Biogen Idec
Biogen Idec extends tender offer to acquire Facet Biotech
Biogen Idec has extended the tender offer by its wholly owned subsidiary, FBC Acquisition, to purchase all of the outstanding shares of Facet Biotech to December 16, 2009, unless otherwise extended. The tender offer was previously set to expire on October ... [Individual.com - 10/19/2009]
First Reported 10/16/2009 - Updated 10/16/2009 - 7 Documents (in Corporate Deals)
Biogen Idec extends bid for Facet Biotech
Biogen Idec extends deadline for hostile takeover bid of Facet Biotech ... [CBS News - 10/16/2009]
First Reported 10/19/2009 - Updated 10/19/2009 - 8 Documents
Food and Drug Administration - Click to view 360-page
Food and Drug Administration
Biogen Idec, Biovitrum to move long-acting hemophilia B therapy into registrational study
- Sweden-based biopharmaceutical company Biovitrum AB (STO: BVT) and US-based Biogen Idec Inc (NASDAQ: BIIB) said today they intend to advance the long-acting, fully-recombinant Factor IX Fc fusion protein (rFIXFc) into a registrational clinical trial ... [Pharmacy Choice - 10/19/2009]
First Reported 10/14/2009 - Updated 10/14/2009 - 3 Documents
Elan Corporation, plc - Click to view image in its original context
Elan Corporation, plc
Zacks Analyst Blog Highlights: American International Group, Morgan Stanley, Elan Corporation,...
BusinessWire - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: ... [Forbes.com - 10/14/2009]
First Reported 10/20/2009 - Updated 10/20/2009 - 1 Documents (in Internet & IT)
Biogen Idec Q3 Profit Increases - Quick Facts
(RTTNews) - Biogen Idec Inc. (BIIB: News ) reported third-quarter net income attributable to the company of $277.663 million or $0.95 per share compared to $206.788 million or $0.70 per share last year.Non-GAAP net income attributable to the company was ... [RTTNews.com - 10/20/2009]
Entities: Biogen Idec
In Focus
Network

Blogs

sort by: Date | Relevance
Biogen Idec Inc. Q3 2009 Earnings Call Transcript [Biotech Sector and Stocks Analysis from Seeking ... - 10/20/2009]
Biogen Idec Inc. (BIIB) Q3 2009 Earnings Call October 20, 2009 8:30 am ETComplete Story » ...
1

  •  
  •  
  •